Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.
CITATION STYLE
Niu, L., Sulek, K., Vasilopoulou, C. G., Santos, A., Wewer Albrechtsen, N. J., Rasmussen, S., … Mann, M. (2021, October 1). Defining NASH from a multi-omics systems biology perspective. Journal of Clinical Medicine. MDPI. https://doi.org/10.3390/jcm10204673
Mendeley helps you to discover research relevant for your work.